Surfaxin lucinactant: Preliminary Phase II data

Preliminary results from an open-label, dose-ranging, North American Phase II trial in 78 evaluable patients

Read the full 153 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE